ArticleEndocrine2025
Integrating ocular and clinical features to enhance intravenous glucocorticoid response prediction in thyroid eye disease: a machine learning approach.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Evaluating and enhancing the performance of large language models in thyroid eye disease through customization and Chain-of-Thought strategies.Scientific reports · 2026Article
- Development and validation of a nomogram for predicting non-response to tocilizumab in thyroid eye disease: a retrospective study.BMC ophthalmology · 2026Article
- Management of Thyroid Eye Disease: A Comparison Between Three Recent Clinical Guidelines.Ophthalmology and therapy · 2026Review
- Multimodal MRI radiomics-clinical fusion model predicts intravenous glucocorticoid response in thyroid eye disease.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposesPredicting intravenous glucocorticoid (IVGC) efficacy in thyroid eye disease (TED) is vital for personalized treatment and minimizing side effects. Current methods haven't fully utilized ocular features. This study aims to integrate ocular features into predictive model to assess their impact on improving IVGC efficacy prediction.
methodsThis retrospective study recruited 130 TED patients who received 4.5 g of IVGC treatment and collected their clinical features. After Least Absolute Shrinkage and Selection Operator (LASSO) regression for feature selection, two key features, lid aperture and CAS, were identified and incorporated into a predictive model. Subsequently, five ocular features were added, resulting in a model using both clinical and ocular features. Six machine learning classifiers were tested on both models, and the performances of two models were compared. The best-performing predictive model was analyzed using SHapley Additive exPlanations (SHAP) to interpret the model.
resultsIn the LASSO regression, CAS and lid aperture were selected as key features for predicting IVGC efficacy. In the model using only clinical features, the best-performing classifier was Logistic Regression, with an AUC of 0.701. However, when ocular features were incorporated, the XGBoost classifier outperformed all others, with the AUC improving to 0.821. SHAP analysis further indicated that conjunctival edema was the most important feature for prediction.
conclusionsThis study identified features associated with the prediction of IVGC efficacy and demonstrated that incorporating ocular features into clinical parameters improves the ability to predict treatment outcomes. Additionally, SHAP analysis highlighted the importance of ocular features in predicting treatment efficacy, providing a basis for further mechanistic exploration.
Indexed as
Identifiers
40549141What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.